

## Keyword index

### Acetylcholine

Molsidomine; Sildenafil; Pulmonary hypertension; Atrial natriuretic peptide; (Chronic hypoxic rats) (Andersen, C.U. (510) 87)

### Adenosine A<sub>1</sub> receptor

Inverse agonism; Constitutive activity; G14T mutant; “Locked-on” phenotype (de Ligt, R.A.F. (510) 1)

### Aldosterone

Urinary bladder; Epithelial Na<sup>+</sup> channel (Burton, T.J. (510) 181)

### Allodynia

N/OFQ (nociceptin/orphanin FQ); NOP receptor antagonist; JTC-801; Hyperalgesia (Tamai, H. (510) 223)

### Alzheimer disease

Calyculin A; Tau; Phosphorylation; Melatonin (Li, X.-C. (510) 25)

### 17β-aminoestrogen

Estradiol; Uterotrophic effect; Estrogenic effect (Lemini, C. (510) 235)

### 17β-Aminoestrogen

Estradiol; Anticoagulant effect; Thrombogenic effect (Lemini, C. (510) 229)

### Anandamide

Cannabinoid; Cross-tolerance; Methanandamide; Tetrahydrocannabinol; Tolerance (Wiley, J.L. (510) 59)

### Angiogenesis

Endothelial cell; Free radical; Nitric oxide; Endothelial nitric oxide synthase (Polytarchou, C. (510) 31)

Diabetes; VEGF (vascular endothelial cell growth factor); Calcium dobesilate; (Rat) (Lameynardie, S. (510) 149)

### Antiarrhythmic action

Terikalant; Cellular electrophysiology; Multichannel block (Biliczki, P. (510) 161)

### Anticoagulant effect

17β-Aminoestrogen; Estradiol; Thrombogenic effect (Lemini, C. (510) 229)

### Antipyrine clearance

Endotoxin; CYP3A2; CYP2C11; P-glycoprotein; (Rat) (Ueyama, J. (510) 127)

### Atosiban

Barusiban; Carbetocin; G-protein coupled receptors; Oxytocin (Gimpl, G. (510) 9)

### Atrial natriuretic peptide

Molsidomine; Sildenafil; Pulmonary hypertension; Acetylcholine; (Chronic hypoxic rats) (Andersen, C.U. (510) 87)

Brain natriuretic peptide; C-type natriuretic peptide; Cyclic GMP protein kinase; (Rabbit) (Zhang, Q. (510) 209)

### Atropine

Diabetic gastroparesis; Postprandial hypertriglyceridemia; *Rheum palmarum* L.; Domperidone (Xie, W. (510) 113)

### Barusiban

Atosiban; Carbetocin; G-protein coupled receptors; Oxytocin (Gimpl, G. (510) 9)

### β-Cyclodextrin

Cytotoxicity; Dehydrocrotonin; Hepatocyte; V79 cell (Corrêa, D.H.A. (510) 17)

### Brain natriuretic peptide

Atrial natriuretic peptide; C-type natriuretic peptide; Cyclic GMP protein kinase; (Rabbit) (Zhang, Q. (510) 209)

### Caco-2 cell line

Tetramethylpyrazine; Cystic fibrosis transmembrane conductance regulator; cAMP; K<sup>+</sup> channel; Membrane permeabilization (Zhu, J.X. (510) 187)

### Calcium dobesilate

Diabetes; VEGF (vascular endothelial cell growth factor); Angiogenesis; (Rat) (Lameynardie, S. (510) 149)

### Calyculin A

Alzheimer disease; Tau; Phosphorylation; Melatonin (Li, X.-C. (510) 25)

### cAMP

Tetramethylpyrazine; Cystic fibrosis transmembrane conductance regulator; K<sup>+</sup> channel; Membrane permeabilization; Caco-2 cell line (Zhu, J.X. (510) 187)

### Cannabinoid

Anandamide; Cross-tolerance; Methanandamide; Tetrahydrocannabinol; Tolerance (Wiley, J.L. (510) 59)

### Capacitance vessel

Urocortin; Corticotropin releasing factor; Mean arterial pressure; Mean circulatory filling pressure; Venous (Abdelrahman, A.M. (510) 107)

### Capacitative Ca<sup>2+</sup> entry

Rat portal vein; Store operated Ca<sup>2+</sup> entry; Cyclopiazonic acid; Niflumic acid (Burt, R.P. (510) 97)

TRPC1; TRPC5; Human epidermoid carcinoma A431 cell; Thapsigargin; Uridine 5'-triphosphate (Yoshida, J. (510) 217)

### **Carbetocin**

Atosiban; Barusiban; G-protein coupled receptors; Oxytocin (Gimpl, G. (510) 9)

### **CB<sub>1</sub>**

Endocannabinoid; Conditioning; Motivation; Food consumption; Knock-out (Hölter, S.M. (510) 69)

### **Cellular electrophysiology**

Terikalan; Antiarrhythmic action; Multichannel block (Biliczki, P. (510) 161)

### **(Chronic hypoxic rats)**

Molsidomine; Sildenafil; Pulmonary hypertension; Acetylcholine; Atrial natriuretic peptide (Andersen, C.U. (510) 87)

### **Conditioning**

CB<sub>1</sub>; Endocannabinoid; Motivation; Food consumption; Knock-out (Hölter, S.M. (510) 69)

### **Constitutive activity**

Adenosine A<sub>1</sub> receptor; Inverse agonism; G14T mutant; "Locked-on" phenotype (de Ligt, R.A.F. (510) 1)

### **Corticotropin releasing factor**

Urocortin; Mean arterial pressure; Mean circulatory filling pressure; Venous; Capacitance vessel (Abdelrahman, A.M. (510) 107)

### **Cross-tolerance**

Anandamide; Cannabinoid; Methanandamide; Tetrahydrocannabinol; Tolerance (Wiley, J.L. (510) 59)

### **Cry j 2**

Pollinosis; Oral tolerance; Immunoprophylaxis; T cell epitope (Murasugi, T. (510) 143)

### **C-type natriuretic peptide**

Atrial natriuretic peptide; Brain natriuretic peptide; Cyclic GMP protein kinase; (Rabbit) (Zhang, Q. (510) 209)

### **Cyclic GMP protein kinase**

Atrial natriuretic peptide; Brain natriuretic peptide; C-type natriuretic peptide; (Rabbit) (Zhang, Q. (510) 209)

### **Cyclopiazonic acid**

Rat portal vein; Capacitative Ca<sup>2+</sup> entry; Store operated Ca<sup>2+</sup> entry; Niflumic acid (Burt, R.P. (510) 97)

### **CYP2C11**

Endotoxin; CYP3A2; P-glycoprotein; Antipyrine clearance; (Rat) (Ueyama, J. (510) 127)

### **CYP3A2**

Endotoxin; CYP2C11; P-glycoprotein; Antipyrine clearance; (Rat) (Ueyama, J. (510) 127)

### **Cystic fibrosis transmembrane conductance regulator**

Tetramethylpyrazine; cAMP; K<sup>+</sup> channel; Membrane permeabilization; Caco-2 cell line (Zhu, J.X. (510) 187)

### **Cytotoxicity**

β-Cyclodextrin; Dehydrocrotonin; Hepatocyte; V79 cell (Corrêa, D.H.A. (510) 17)

### **Dehydrocrotonin**

β-Cyclodextrin; Cytotoxicity; Hepatocyte; V79 cell (Corrêa, D.H.A. (510) 17)

### **Diabetes**

VEGF (vascular endothelial cell growth factor); Angiogenesis; Calcium dobesilate; (Rat) (Lameynardie, S. (510) 149)

### **Diabetic gastroparesis**

Postprandial hypertriglyceridemia; *Rheum palmatum* L.; Domperidone; Atropine (Xie, W. (510) 113)

### **DNA synthesis**

Leucine; Proliferation; Hepatocyte (Kimura, M. (510) 167)

### **Domperidone**

Diabetic gastroparesis; Postprandial hypertriglyceridemia; *Rheum palmatum* L.; Atropine (Xie, W. (510) 113)

### **Dopamine D1/D2 receptor stimulation**

Jaw movement; Nucleus accumbens shell; Retrorubral field; Ventral pallidum; GABA<sub>A</sub> receptor; (Rat) (Uchida, T. (510) 39)

### **Dopamine D1-like receptor**

Nephrosis; Proteinuria; Puromycin aminonucleoside; Zelandopam (Yatsu, T. (510) 121)

### **Dorsal root ganglion**

Sensory neuron; Tetrodotoxin-resistant sodium channel; Tetrodotoxin-sensitive sodium channel; Ralfinamide; NW-1029 (Stummann, T.C. (510) 197)

### **Endocannabinoid**

CB<sub>1</sub>; Conditioning; Motivation; Food consumption; Knock-out (Hölter, S.M. (510) 69)

### **Endothelial cell**

Angiogenesis; Free radical; Nitric oxide; Endothelial nitric oxide synthase (Polytarchou, C. (510) 31)

### **Endothelial nitric oxide synthase**

Angiogenesis; Endothelial cell; Free radical; Nitric oxide (Polytarchou, C. (510) 31)

### **Endotoxin**

CYP3A2; CYP2C11; P-glycoprotein; Antipyrine clearance; (Rat) (Ueyama, J. (510) 127)

### **Epithelial Na<sup>+</sup> channel**

Urinary bladder; Aldosterone (Burton, T.J. (510) 181)

### **Estradiol**

17β-Aminoestrogen; Anticoagulant effect; Thrombogenic effect (Lemini, C. (510) 229)

17β-aminoestrogen; Uterotrophic effect; Estrogenic effect (Lemini, C. (510) 235)

### **Estrogenic effect**

17β-aminoestrogen; Estradiol; Uterotrophic effect (Lemini, C. (510) 235)

### **Food consumption**

CB<sub>1</sub>; Endocannabinoid; Conditioning; Motivation; Knock-out (Hölter, S.M. (510) 69)

### **Free radical**

Angiogenesis; Endothelial cell; Nitric oxide; Endothelial nitric oxide synthase (Polytarchou, C. (510) 31)

**Frontal cortex**

Serotonin (5-hydroxytryptamine, 5-HT); Microdialysis; Paroxetine; *N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(pyridinyl)cyclohexanecarboxamide (WAY-100635); 5-HT<sub>1A</sub> receptor; 8-Hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT) (Hughes, Z.A. (510) 49)

**G14T mutant**

Adenosine A<sub>1</sub> receptor; Inverse agonism; Constitutive activity; “Locked-on” phenotype (de Ligt, R.A.F. (510) 1)

**GABA<sub>A</sub> receptor**

Jaw movement; Nucleus accumbens shell; Retrorubral field; Ventral pallidum; Dopamine D1/D2 receptor stimulation; (Rat) (Uchida, T. (510) 39)

**G-protein coupled receptors**

Atosiban; Barusiban; Carbetocin; Oxytocin (Gimpl, G. (510) 9)

**Hepatocyte**

β-Cyclodextrin; Cytotoxicity; Dehydrocrotonin; V79 cell (Corrêa, D.H.A. (510) 17)

Leucine; DNA synthesis; Proliferation (Kimura, M. (510) 167)

**hERG**

Trazodone; QT-interval; Polymorphous ventricular tachycardia; Torsade de pointes (Tarantino, P. (510) 75)

**Human epidermoid carcinoma A431 cell**

TRPC1; TRPC5; Capacitative Ca<sup>2+</sup> entry; Thapsigargin; Uridine 5'-triphosphate (Yoshida, J. (510) 217)

**5-HT<sub>1A</sub> receptor**

Serotonin (5-hydroxytryptamine, 5-HT); Microdialysis; Frontal cortex; Paroxetine; *N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(pyridinyl)-cyclohexanecarboxamide (WAY-100635); 8-Hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT) (Hughes, Z.A. (510) 49)

**8-Hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT)**

Serotonin (5-hydroxytryptamine, 5-HT); Microdialysis; Frontal cortex; Paroxetine; *N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(pyridinyl)-cyclohexanecarboxamide (WAY-100635); 5-HT<sub>1A</sub> receptor (Hughes, Z.A. (510) 49)

**Hyperalgesia**

N/OFQ (nociceptin/orphanin FQ); NOP receptor antagonist; JTC-801; Allodynia (Tamai, H. (510) 223)

**Immunoprophylaxis**

Cry j 2; Pollinosis; Oral tolerance; T cell epitope (Murasugi, T. (510) 143)

**Inverse agonism**

Adenosine A<sub>1</sub> receptor; Constitutive activity; G14T mutant; “Locked-on” phenotype (de Ligt, R.A.F. (510) 1)

**Jaw movement**

Nucleus accumbens shell; Retrorubral field; Ventral pallidum; GABA<sub>A</sub> receptor; Dopamine D1/D2 receptor stimulation; (Rat) (Uchida, T. (510) 39)

**JTC-801**

N/OFQ (nociceptin/orphanin FQ); NOP receptor antagonist; Allodynia; Hyperalgesia (Tamai, H. (510) 223)

**K<sup>+</sup> channel**

Tetramethylpyrazine; Cystic fibrosis transmembrane conductance regulator; cAMP; Membrane permeabilization; Caco-2 cell line (Zhu, J.X. (510) 187)

**Knock-out**

CB<sub>1</sub>; Endocannabinoid; Conditioning; Motivation; Food consumption (Hölter, S.M. (510) 69)

**Leucine**

DNA synthesis; Proliferation; Hepatocyte (Kimura, M. (510) 167)

**“Locked-on” phenotype**

Adenosine A<sub>1</sub> receptor; Inverse agonism; Constitutive activity; G14T mutant (de Ligt, R.A.F. (510) 1)

**Lung injury**

Nitric oxide; Oleic acid; Rho-kinase; Y-27632 (Köksel, O. (510) 135)

**Mean arterial pressure**

Urocortin; Corticotropin releasing factor; Mean circulatory filling pressure; Venous; Capacitance vessel (Abdelrahman, A.M. (510) 107)

**Mean circulatory filling pressure**

Urocortin; Corticotropin releasing factor; Mean arterial pressure; Venous; Capacitance vessel (Abdelrahman, A.M. (510) 107)

**Melatonin**

Alzheimer disease; Calyculin A; Tau; Phosphorylation (Li, X.-C. (510) 25)

**Membrane permeabilization**

Tetramethylpyrazine; Cystic fibrosis transmembrane conductance regulator; cAMP; K<sup>+</sup> channel; Caco-2 cell line (Zhu, J.X. (510) 187)

**Methanandamide**

Anandamide; Cannabinoid; Cross-tolerance; Tetrahydrocannabinol; Tolerance (Wiley, J.L. (510) 59)

**Microdialysis**

Serotonin (5-hydroxytryptamine, 5-HT); Frontal cortex; Paroxetine; *N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(pyridinyl)cyclohexanecarboxamide (WAY-100635); 5-HT<sub>1A</sub> receptor; 8-Hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT) (Hughes, Z.A. (510) 49)

**Molsidomine**

Sildenafil; Pulmonary hypertension; Acetylcholine; Atrial natriuretic peptide; (Chronic hypoxic rats) (Andersen, C.U. (510) 87)

**Motivation**

CB<sub>1</sub>; Endocannabinoid; Conditioning; Food consumption; Knock-out (Hölter, S.M. (510) 69)

**Multichannel block**

Terikalant; Cellular electrophysiology; Antiarrhythmic action (Biliczki, P. (510) 161)

***N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(pyridinyl)cyclohexanecarboxamide (WAY-100635)**

Serotonin (5-hydroxytryptamine, 5-HT); Microdialysis; Frontal cortex; Paroxetine; 5-HT<sub>1A</sub> receptor; 8-Hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT) (Hughes, Z.A. (510) 49)

**Nephrosis**

Dopamine D1-like receptor; Proteinuria; Puromycin aminonucleoside; Zelandopam (Yatsu, T. (510) 121)

**Niflumic acid**

Rat portal vein; Capacitative Ca<sup>2+</sup> entry; Store operated Ca<sup>2+</sup> entry; Cyclopiazonic acid (Burt, R.P. (510) 97)

**Nitric oxide**

Angiogenesis; Endothelial cell; Free radical; Endothelial nitric oxide synthase (Polytarchou, C. (510) 31)

Lung injury; Oleic acid; Rho-kinase; Y-27632 (Köksel, O. (510) 135)

**N/OFQ (nociceptin/orphanin FQ)**

NOP receptor antagonist; JTC-801; Allodynia; Hyperalgesia (Tamai, H. (510) 223)

**NOP receptor antagonist**

N/OFQ (nociceptin/orphanin FQ); JTC-801; Allodynia; Hyperalgesia (Tamai, H. (510) 223)

**Nucleus accumbens shell**

Jaw movement; Retrorubral field; Ventral pallidum; GABA<sub>A</sub> receptor; Dopamine D1/D2 receptor stimulation; (Rat) (Uchida, T. (510) 39)

**NW-1029**

Dorsal root ganglion; Sensory neuron; Tetrodotoxin-resistant sodium channel; Tetrodotoxin-sensitive sodium channel; Ralfinamide (Stummann, T.C. (510) 197)

**Oleic acid**

Lung injury; Nitric oxide; Rho-kinase; Y-27632 (Köksel, O. (510) 135)

**Oral tolerance**

Cry j 2; Pollinosis; Immunoprophylaxis; T cell epitope (Murasugi, T. (510) 143)

**Oxytocin**

Atosiban; Barusiban; Carbetocin; G-protein coupled receptors (Gimpl, G. (510) 9)

**Paroxetine**

Serotonin (5-hydroxytryptamine, 5-HT); Microdialysis; Frontal cortex; *N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(pyridinyl)cyclohexanecarboxamide (WAY-100635); 5-HT<sub>1A</sub> receptor; 8-Hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT) (Hughes, Z.A. (510) 49)

**P-glycoprotein**

Endotoxin; CYP3A2; CYP2C11; Antipyrine clearance; (Rat) (Ueyama, J. (510) 127)

**Phosphorylation**

Alzheimer disease; Calyculin A; Tau; Melatonin (Li, X.-C. (510) 25)

**Pollinosis**

Cry j 2; Oral tolerance; Immunoprophylaxis; T cell epitope (Murasugi, T. (510) 143)

**Polymorphous ventricular tachycardia**

Trazodone; QT-interval; hERG; Torsade de pointes (Tarantino, P. (510) 75)

**Postprandial hypertriglyceridemia**

Diabetic gastroparesis; *Rheum palmatum* L.; Domperidone; Atropine (Xie, W. (510) 113)

**Proliferation**

Leucine; DNA synthesis; Hepatocyte (Kimura, M. (510) 167)

**Proteinuria**

Dopamine D1-like receptor; Nephrosis; Puromycin aminonucleoside; Zelandopam (Yatsu, T. (510) 121)

**Pulmonary hypertension**

Molsidomine; Sildenafil; Acetylcholine; Atrial natriuretic peptide; (Chronic hypoxic rats) (Andersen, C.U. (510) 87)

**Puromycin aminonucleoside**

Dopamine D1-like receptor; Nephrosis; Proteinuria; Zelandopam (Yatsu, T. (510) 121)

**QT-interval**

Trazodone; hERG; Polymorphous ventricular tachycardia; Torsade de pointes (Tarantino, P. (510) 75)

**(Rabbit)**

Atrial natriuretic peptide; Brain natriuretic peptide; C-type natriuretic peptide; Cyclic GMP protein kinase (Zhang, Q. (510) 209)

**Ralfinamide**

Dorsal root ganglion; Sensory neuron; Tetrodotoxin-resistant sodium channel; Tetrodotoxin-sensitive sodium channel; NW-1029 (Stummann, T.C. (510) 197)

**(Rat)**

Jaw movement; Nucleus accumbens shell; Retrorubral field; Ventral pallidum; GABA<sub>A</sub> receptor; Dopamine D1/D2 receptor stimulation (Uchida, T. (510) 39)

Endotoxin; CYP3A2; CYP2C11; P-glycoprotein; Antipyrine clearance (Ueyama, J. (510) 127)

Diabetes; VEGF (vascular endothelial cell growth factor); Angiogenesis; Calcium dobesilate (Lameynardie, S. (510) 149)

**Rat portal vein**

Capacitative Ca<sup>2+</sup> entry; Store operated Ca<sup>2+</sup> entry; Cyclopiazonic acid; Niflumic acid (Burt, R.P. (510) 97)

**Retrorubral field**

Jaw movement; Nucleus accumbens shell; Ventral pallidum; GABA<sub>A</sub> receptor; Dopamine D1/D2 receptor stimulation; (Rat) (Uchida, T. (510) 39)

***Rheum palmatum* L.**

Diabetic gastroparesis; Postprandial hypertriglyceridemia; Domperidone; Atropine (Xie, W. (510) 113)

**Rho-kinase**

Lung injury; Nitric oxide; Oleic acid; Y-27632 (Köksel, O. (510) 135)

**Sensory neuron**

Dorsal root ganglion; Tetrodotoxin-resistant sodium channel; Tetrodotoxin-sensitive sodium channel; Ralfinamide; NW-1029 (Stummann, T.C. (510) 197)

**Serotonin (5-hydroxytryptamine, 5-HT)**

Microdialysis; Frontal cortex; Paroxetine; *N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(pyridinyl)cyclohexanecarboxamide (WAY-100635); 5-HT<sub>1A</sub> receptor; 8-Hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT) (Hughes, Z.A. (510) 49)

**Sildenafil**

Molsidomine; Pulmonary hypertension; Acetylcholine; Atrial natriuretic peptide; (Chronic hypoxic rats) (Andersen, C.U. (510) 87)

**Store operated Ca<sup>2+</sup> entry**

Rat portal vein; Capacitative Ca<sup>2+</sup> entry; Cyclopiazonic acid; Niflumic acid (Burt, R.P. (510) 97)

**T cell epitope**

Cry j 2; Pollinosis; Oral tolerance; Immunoprophylaxis (Murasugi, T. (510) 143)

- Tau**  
Alzheimer disease; Calyculin A; Phosphorylation; Melatonin (Li, X.-C. (510) 25)
- Terikalant**  
Cellular electrophysiology; Antiarrhythmic action; Multichannel block (Biliczki, P. (510) 161)
- Tetrahydrocannabinol**  
Anandamide; Cannabinoid; Cross-tolerance; Methanandamide; Tolerance (Wiley, J.L. (510) 59)
- Tetramethylpyrazine**  
Cystic fibrosis transmembrane conductance regulator; cAMP; K<sup>+</sup> channel; Membrane permeabilization; Caco-2 cell line (Zhu, J.X. (510) 187)
- Tetrodotoxin-resistant sodium channel**  
Dorsal root ganglion; Sensory neuron; Tetrodotoxin-sensitive sodium channel; Ralfinamide; NW-1029 (Stummann, T.C. (510) 197)
- Tetrodotoxin-sensitive sodium channel**  
Dorsal root ganglion; Sensory neuron; Tetrodotoxin-resistant sodium channel; Ralfinamide; NW-1029 (Stummann, T.C. (510) 197)
- Thapsigargin**  
TRPC1; TRPC5; Capacitative Ca<sup>2+</sup> entry; Human epidermoid carcinoma A431 cell; Uridine 5'-triphosphate (Yoshida, J. (510) 217)
- Thrombogenic effect**  
17β-Aminoestrogen; Estradiol; Anticoagulant effect (Lemini, C. (510) 229)
- Tolerance**  
Anandamide; Cannabinoid; Cross-tolerance; Methanandamide; Tetrahydrocannabinol (Wiley, J.L. (510) 59)
- Torsade de pointes**  
Trazodone; QT-interval; hERG; Polymorphous ventricular tachycardia (Tarantino, P. (510) 75)
- Trazodone**  
QT-interval; hERG; Polymorphous ventricular tachycardia; Torsade de pointes (Tarantino, P. (510) 75)
- TRPC1**  
TRPC5; Capacitative Ca<sup>2+</sup> entry; Human epidermoid carcinoma A431 cell; Thapsigargin; Uridine 5'-triphosphate (Yoshida, J. (510) 217)
- TRPC5**  
TRPC1; Capacitative Ca<sup>2+</sup> entry; Human epidermoid carcinoma A431 cell; Thapsigargin; Uridine 5'-triphosphate (Yoshida, J. (510) 217)
- Uridine 5'-triphosphate**  
TRPC1; TRPC5; Capacitative Ca<sup>2+</sup> entry; Human epidermoid carcinoma A431 cell; Thapsigargin (Yoshida, J. (510) 217)
- Urinary bladder**  
Epithelial Na<sup>+</sup> channel; Aldosterone (Burton, T.J. (510) 181)
- Urocortin**  
Corticotropin releasing factor; Mean arterial pressure; Mean circulatory filling pressure; Venous; Capacitance vessel (Abdelrahman, A.M. (510) 107)
- Uterotrophic effect**  
17β-aminoestrogen; Estradiol; Estrogenic effect (Lemini, C. (510) 235)
- V79 cell**  
β-Cyclodextrin; Cytotoxicity; Dehydrocrotonin; Hepatocyte (Corrêa, D.H.A. (510) 17)
- VEGF (vascular endothelial cell growth factor)**  
Diabetes; Angiogenesis; Calcium dobesilate; (Rat) (Lameynardie, S. (510) 149)
- Venous**  
Urocortin; Corticotropin releasing factor; Mean arterial pressure; Mean circulatory filling pressure; Capacitance vessel (Abdelrahman, A.M. (510) 107)
- Ventral pallidum**  
Jaw movement; Nucleus accumbens shell; Retrorubral field; GABA<sub>A</sub> receptor; Dopamine D1/D2 receptor stimulation; (Rat) (Uchida, T. (510) 39)
- Y-27632**  
Lung injury; Nitric oxide; Oleic acid; Rho-kinase (Köksel, O. (510) 135)
- Zelandopam**  
Dopamine D1-like receptor; Nephrosis; Proteinuria; Puromycin amino-nucleoside (Yatsu, T. (510) 121)